Federal Circuit Scrutinizes Injunction on Eylea Biosimilars Amid Patent Dispute

Regeneron Pharmaceuticals Inc. is currently navigating a significant legal challenge as a Federal Circuit panel reviews a court order that blocks the release of biosimilar versions of its Eylea eye medication. The case involves two companies contesting the injunction, which is crucial for maintaining their market entry plans. The proceedings shed light on the complexities of patent litigation in the pharmaceutical sector and underscore the impact of potential biosimilar competition on established biologic drugs. To explore the ongoing legal battle in detail, the Law360 article offers further insights into this case. For more information, read about the challenges faced by Regeneron Pharmaceuticals on Law360.